Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew    SN.   GB0009223206

SMITH & NEPHEW (SN.)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

Smith & Nephew : UK's NICE publishes a Medtech innovation briefing on PICO for the prophylactic use in surgically closed incisions to reduce surgical site complications

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/22/2018 | 01:54pm CEST

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of PICO Single Use Negative Pressure Wound Therapy (sNPWT).

The MIB reports the prophylactic use of PICO as a potentially more effective alternative to standard surgical dressings in the prevention of surgical site complications (SSCs). This is the first and only MIB published by NICE on an NPWT device for preventing SSCs.

Complications from surgical incisions are a significant economic and human burden, costing an approximate GBP1 billion1 to the NHS each year and contributing to significant morbidity and mortality in the UK and globally. A recent World Union of Wound Healing Societies consensus guidelines reports that up to 60% of surgical site infections (SSIs) are preventable2.

The prophylactic use of the PICO system is proven to be effective in reducing SSCs, including SSIs and dehiscence (wound rupturing) of the surgical incision, in patients at elevated risk of SSCs7.

The PICO dressing has a proprietary AIRLOCK Technology that uniformly and consistently delivers NPWT across a surgical incision and the surrounding zone of injury generated naturally by the incision itself3,4. This proprietary feature is designed to help reduce the risk of wound complications by reducing post-operative fluid, swelling and associated tension around a closed surgical incision compared with standard dressings5,6. The combination of these actions helps reduce the risk of surgical wound dehiscence7 and SSIs7, the 2 most common SSCs.

Evidence shows how the prophylactic use of PICO resulted in fewer complications, and in earlier discharge from hospitals, reducing length of stay, on average by more than 8 days, in closed laparotomy wounds after abdominal surgery8, which has the potential to release bed days for the NHS. In patients undergoing primary hip and knee arthroplasties, it was estimated that care with PICO enabled cost savings of more than GBP7,000 per high-risk patient (BMI 35 or ASA 3) compared with care with standard dressings9.

Ms Pauline Whitehouse, Consultant General and Colorectal Surgeon, Worthing Hospital, said, 'Following the introduction of PICO into our Trust for moderate- to high-risk incisions, we quickly noticed a significant reduction in superficial surgical site infections. We have now introduced PICO across the Trust and are seeing similar reductions in infective complications for other specialities'.

MIBs are objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. They are NICE advice, designed to support NHS and social care commissioners and staff who are considering using new medical devices, and other medical or diagnostic technologies. The briefing will help avoid the need for organisations to produce similar information locally, saving staff time and resources. MIBs are commissioned by NHS England and produced in support of the NHS 5-Year Forward View, specifically as one of a number of steps that will accelerate innovation in new treatments and diagnostics.

As part of the MIB, NICE conducted a thorough review of the published and peer-reviewed data from a variety of meta-analyses and randomised controlled trials (RCTs). The effectiveness of PICO in reducing SSCs has been examined in 10 RCTs and multiple observational studies. A recently published 1,839 patient meta-analysis demonstrated the efficacy of PICO, used prophylactically, significantly reducing SSIs by 58% in closed surgical incisions compared with standard care5.

PICO is suitable for use in both hospital and community settings, and is approved for a number of indications, including surgically closed incision sites.

'NICE MIBs are a great resource for NHS organisations, and are often a reference used by healthcare systems beyond the UK. Today we are delighted to see the NICE MIB support for the prophylactic use of PICO as an effective alternative for clinicians who look to reduce their rates of surgical site complications. This will provide them with the confidence to use PICO for their at-risk patients and procedures, in support of their efforts to achieve better economic and clinical outcomes,' said Paolo Di Vincenzo, Smith & Nephew's SVP of Advanced Wound Management. 'With PICO, we are keeping Smith & Nephew at the forefront of delivering pioneering solutions that continue to improve current standards of care, by reducing the burden and delivering better clinical and economic outcomes. PICO has shown significant clinical results in reducing life-threatening infections on closed surgical incisions, which has contributed significantly to improved patient outcomes, in a cost-effective portable solution'.

50-patient study; length of stay reduced: PICO 6.1 days; control group 14.7 days; p

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SMITH & NEPHEW
06/22SMITH & NEPHEW : UK's NICE publishes a Medtech innovation briefing on PICO for t..
AQ
06/21“PERFORMANCE-LED PROCUREMENT : Why innovation should be front and centre&r..
PU
06/15SMITH & NEPHEW : Steadman Philippon Research Institute and Smith & Nephew Host F..
AQ
06/12SMITH & NEPHEW : Judicial Panel on Multidistrict Litigation Issues Order on Smit..
AQ
06/01WOUND DEBRIDEMENT DEVICES : Full in-Depth Analysis by Regional Outlook, Growth, ..
AQ
05/25SMITH & NEPHEW : Orthoalign System. Make-Smith & Nephew/Zimmer. Annexure Attache..
AQ
05/24POLARITYTE : Announces Howard Hechler from Smith & Nephew as the New Chief Busin..
AQ
05/24BIOCENTURY - MANAGEMENT TRACKS : Lilly, LogicBio
AQ
05/17SMITH & NEPHEW : An Application for the Trademark "BBT" Has Been Filed by Smith ..
AQ
05/17SMITH & NEPHEW : An Application for the Trademark "PFS" Has Been Filed by Smith ..
AQ
More news
News from SeekingAlpha
06/11Sell-siders weigh in on possible Boston Scientific - Stryker marriage 
05/29My IMF Portfolio's Top 30 Holdings (Part 1) 
05/14SMITH & NEPHEW : Not Attractive Enough 
05/04Smith & Nephew's (SNN) CEO Olivier Bohuon on Q1 2018 Results - Earnings Call .. 
05/03Smith & Nephew plc 2018 Q1 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 5 033 M
EBIT 2018 1 018 M
Net income 2018 665 M
Debt 2018 1 104 M
Yield 2018 1,96%
P/E ratio 2018 23,51
P/E ratio 2019 19,95
EV / Sales 2018 3,37x
EV / Sales 2019 3,20x
Capitalization 15 849 M
Chart SMITH & NEPHEW
Duration : Period :
Smith & Nephew Technical Analysis Chart | SN. | GB0009223206 | 4-Traders
Technical analysis trends SMITH & NEPHEW
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 18,7 $
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Namal Nawana Chief Executive Officer & Executive Director
Roberto Quarta Chairman
Matthew R. Stober President-Global Operations
Graham James Baker Chief Financial Officer & Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SMITH & NEPHEW6.83%15 849
STRYKER CORPORATION9.49%63 359
WRIGHT MEDICAL GROUP NV17.84%2 887
JAPAN LIFELINE CO., LTD.14.71%2 169
GLAUKOS CORP73.53%1 554
CERUS CORPORATION114.50%946